Quest Diagnostics (NY:DGX)

233.33 UNCHANGED

Delayed Quote Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Quest Diagnostics

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test

December 19, 2024

Quest to Support Mainz Biomed’s ReconAAsense FDA Study and Has Option to Commercialize Test Kit Assuming FDA Approval

From Mainz BioMed NV

Via GlobeNewswire

Tesla To Rally More Than 11%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

December 17, 2024

Via Benzinga

This Tesla Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗

December 17, 2024

Via Benzinga

The Analyst Landscape: 8 Takes On Quest Diagnostics ↗

December 10, 2024

Via Benzinga

(DGX) - Analyzing Quest Diagnostics's Short Interest ↗

December 02, 2024

Via Benzinga

How Is The Market Feeling About Quest Diagnostics? ↗

November 11, 2024

Via Benzinga

What Analysts Are Saying About Quest Diagnostics Stock ↗

October 23, 2024

Via Benzinga

Guardant Health Stock Sees RS Rating Jump To 83 ↗

November 20, 2024

On Wednesday, Guardant Health stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83.

Via Investor's Business Daily

Navigating Earnings Season: Weather Any Storm ↗

November 16, 2024

The consequences of hurricanes like Helene and Milton are—typically—quickly shrugged aside by markets as one-off events. That is mostly correct. But not entirely so. For some companies, the revenue and...

Via Talk Markets

Donald Trump's Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare ↗

November 09, 2024

Trump's second term could bring significant changes to U.S. healthcare, with cuts to ACA subsidies and potential Medicare privatization.

Via Benzinga

Topics Government

Laboratory Corp Q3 Earnings Beat Street View, Investors Overlook Hurricane Helene Impact ↗

October 24, 2024

LabCorp Q3 2024 EPS beats expectations at $3.50, with 7.4% revenue growth to $3.28B. Adjusted EPS guidance revised due to weather.

Via Benzinga

Topics Earnings

Cracking The Code: Understanding Analyst Reviews For Quest Diagnostics ↗

October 23, 2024

Via Benzinga

Earnings Preview: Quest Diagnostics ↗

October 21, 2024

Via Benzinga

Looking Into Quest Diagnostics's Recent Short Interest ↗

October 21, 2024

Via Benzinga

Decoding 7 Analyst Evaluations For Quest Diagnostics ↗

October 07, 2024

Via Benzinga

This Snap Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday ↗

October 23, 2024

Via Benzinga

Quest Diagnostics Posts Upbeat Results, Joins GM, Philip Morris And Other Big Stocks Moving Higher On Tuesday ↗

October 22, 2024

Via Benzinga

Quest Diagnostics CEO Touts 'New Customer Wins' In Q3, Expects Earnings Growth In 2025 ↗

October 22, 2024

Quest Diagnostics reports strong Q3 with 8.5% sales growth, raises 2024 revenue guidance to $9.80 billion-$9.85 billion, citing acquisitions and new customer wins.

Via Benzinga

Uber To Rally Over 33%? Here Are 10 Top Analyst Forecasts For Monday ↗

October 07, 2024

Via Benzinga

What Analysts Are Saying About Quest Diagnostics Stock ↗

August 27, 2024

Via Benzinga

Uncovering Dividend Opportunities with NYSE:DGX. ↗

July 25, 2024

Analyzing QUEST DIAGNOSTICS INC (NYSE:DGX)'s Dividend Potential.

Via Chartmill

5 Analysts Assess Quest Diagnostics: What You Need To Know ↗

July 24, 2024

Via Benzinga

Diagnostic Giants Labcorp, Roche To Ramp Up Testing Capacity Amid Global Concerns Over New Mpox Strain ↗

August 26, 2024

Labcorp considers boosting its mpox testing capacity as the WHO declares a global health emergency. Companies like Roche and Quest Diagnostics are also monitoring demand and expanding testing...

Via Benzinga

8 Health Care Stocks With Whale Alerts In Today's Session ↗

August 01, 2024

Via Benzinga

LabCorp's Stock Soars After Q2 Performance, Analyst Highlights Strong Position In Healthcare Sector ↗

August 01, 2024

LabCorp reported Q2 2024 adjusted EPS of $3.94, surpassing expectations of $3.78. Sales increased by 6.2% to $3.22 billion, driven by organic revenue growth and acquisitions. LabCorp revised its 2024...

Via Benzinga

Quest Diagnostics' Q2 Earnings Performance Suggests Stable Stock, Modest Growth Ahead, Analyst Says ↗

July 23, 2024

Quest Diagnostics reported a second-quarter adjusted EPS of $2.35, surpassing the consensus of $2.34. Sales rose 2.5% year-over-year to $2.39 billion. The company raised its fiscal year 2024 revenue...

Via Benzinga

Small-Cap Gains Resume Ahead Of Major Tech Earnings; UPS Faces Worst Day Ever, Bitcoin Dips Below $66,000: What's Driving Markets Tuesday? ↗

July 23, 2024

Tuesday's Wall Street session was mixed, with small-caps outperforming large-caps as investors awaited earnings from Alphabet Inc. and Tesla Inc.

Via Benzinga

DGX Stock Earnings: Quest Diagnostics Beats EPS, Beats Revenue for Q2 2024 ↗

July 23, 2024

DGX stock results show that Quest Diagnostics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

US Stock Futures Little Changed As Traders Brace For Q2 Reports From Alphabet, Tesla: 'There Remains Strong Fundamental Support For Large Caps,' Says Economist ↗

July 23, 2024

The market mood turned jittery after Monday’s rebound, with index futures trading on either side of the unchanged line early Tuesday. The apprehensions reflect uncertainties regarding geopolitics,...

Via Benzinga

Topics Artificial Intelligence

Tesla, Alphabet, GM, Ford Lead Earnings Parade This Week As Market Struggles To Sustain The Summer Rally ↗

July 21, 2024

The earnings parade continues this week with a slightly accelerated tempo as analysts brace for a healthy reporting season.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.